In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DBV Technologies SA

www.dbv-technologies.com

Latest From DBV Technologies SA

Resubmission After Withdrawal: US FDA’s Mavenclad Approval Acknowledges Long Regulatory History

EMD Serono’s multiple sclerosis drug joins small cadre of products that survived a refuse to file letter and NDA withdrawal; chart details recent RTFs and application withdrawals.

Drug Approval Standards Drug Review

Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks

Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.

Financing Business Strategies

Aimmune Lays Foundations In Europe For Lead Peanut Allergy Therapeutic

With Aimmune’s AR101 oral immunotherapeutic nearing the market in the EU and US, the company sketches out its European business strategy after ARTEMIS meets its primary endpoint.

 

Immune Disorders Advertising, Marketing & Sales

US FDA's Shutdown Offers One Possible Winner

For most sponsors, shutdown's impact won’t be too dramatic – but for two peanut allergy companies, the stoppage had very different implications. 
Drug Review Drug Approval Standards
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Transdermal
    • Vaccines
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • DBV Technologies SA
  • Senior Management
  • Daniel Tassé , CEO
    Sébastien Robitaille, Deputy CFO
    Hugh A Sampson, MD, CSO & Interim CMO
    Susanna Mesa, CBO
  • Contact Info
  • DBV Technologies SA
    Phone: (33) 1 55 42 78 78
    177-181 avenue Pierre Brossolette
    Montrouge, 92120
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register